NL-OMON49692已完成不适用
Dose REduction Strategy Study of TNF inhibitors in Psoriatic arthritis and axial Spondyloarthritis patients. - DRESS-PS
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Eligible patients are >= 16 years of age at the time of signing the informed
- •consent form AND
- •1) have peripheral SpA of the psoriatic arthritis subtype diagnosed clinically
- •by the rheumatologist , supported by the Classification Criteria for Psoriatic
- •Arthritis (CASPAR) and/or
- •2) have axial SpA of the axial spondyloarthritis subtype, supported by the
- •Assessment of SpondyloArthritis international Society (ASAS) classification
- •criteria for axSpA, AND
- •- Are using full dose, or at least > 50% of the authorized defined daily dose
- •(DDD), of an originator or biosimilar TNFi (adalimumab, certolizumab,
- •etanercept, golimumab, infliximab);
- •- Patients have to have stable LDA, Psoriatic Arthritis Disease Activity Score
- •(PASDAS) <= 3.2 and a skin measure of body surface area involvement (modified
- •BSA) using a target of 3% as used by rheumatologists in clinical practice for
- •PsA and/or Ankylosing Spondylitis Disease Activity Score (ASDAS) < 2.1 and an
- •absence of active extra-axial symptoms such as Crohn*s disease, uveitis,
- •colitis or psoriasis for axSpA, for at least 6 months, or when formal
- •measurements are not available, judgement of physician and patient.
排除标准
- •- Previous recorded unsuccessful dose reduction of TNFi in the previous 24
- •- Comorbidities expected to hamper successful dose reduction (e g Crohns
- •disease, Ulcerative colitis, Psoriasis, Uveitis),
- •- Not able to have 12 months follow-up (life expectancy, planned relocation),
- •- Not able to measure outcome (language, other limitations)
研究者
相似试验
尚未招募
1 期
Investigations into a TNF inhibitor to limit complications following complex surgeryVascular surgerySurgery - Other surgeryACTRN12608000001392St.Vincent's Health Melbourne30
撤回
4 期
Trough level-based dose reduction during infliximab maintenance treatment in Crohn*s diseaseCrohn's diseaseNL-OMON40729Academisch Medisch Centrum54
招募中
不适用
Study of efficacy and safety of dose reduction in the oral cavity by target volume definition using PET/CT for intensity-modulated radiation therapy of head and neck cancersHead-and-neck cancerJPRN-UMIN000033007Juntendo University,Graduate School of Medicine,Department of Radiation Oncology10
已完成
不适用
Dose REduction Strategy Study of TNF inhibitors in Psoriatic arthritis and axial Spondyloarthritis patients.- Psoriatic arthritis, Axial Spondyloarthritis, Dose reduction, TNF inhibitors- Artritis psoriatica, Axiale Spondylartritis, Dosis reductie, TNF remmersNL-OMON29006Sint Maartenskliniek95
已完成
不适用
Efficacy of dose modification based on therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections associated with hematological diseasesInvasive fungal infections associated with hematological diseasesJPRN-UMIN000005639Department of Hematology and Oncology, University of Tokyo Hospital50